Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1220 participants.

Also called NCT06401616

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,220 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06401616
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06401616. Randomized; single masking; primary purpose treatment. Start 2024-05-21 (actual); primary completion 2028-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
Condition
Left Atrial Appendage Absent
Condition
Anticoagulant Adverse Reaction
Intervention (Drug)
OAC will be discontinued for the duration of the trial
Lead sponsor
Odense University Hospital (class: other)
Collaborator
Copenhagen University Hospital, Rigshospitalet (class: other)
Collaborator
Gødstrup Hospital (class: other)
Collaborator
Aarhus University Hospital (class: other)
Collaborator
Aalborg University Hospital (class: other)
Collaborator
Population Health Research Institute (class: other)
Collaborator
Region of Southern Denmark (class: other)

Record details

Record id
cardio:ct-nct06401616
Content hash
6c64096e35e1f022d395099ffac081fb599341f17b0060c30e8fa0763c5fd675